Meloxicam/rizatriptan

Meloxicam/rizatriptan
Combination of
MeloxicamNonsteroidal anti-inflammatory drug
Rizatriptanserotonin (5-HT) 1B/1D receptor agonist (triptan)
Clinical data
Trade namesSymbravo
AHFS/Drugs.comMonograph
MedlinePlusa625033
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine.[1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1] It is taken by mouth.[1]

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]

Medical uses

Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.[1][3]

Society and culture

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]

References

  1. ^ a b c d e "Symbravo- meloxicam, rizatriptan tablet". DailyMed. 24 February 2025. Retrieved 7 July 2025.
  2. ^ a b "Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" (Press release). Axsome Therapeutics. 30 January 2025. Retrieved 7 February 2025 – via GlobeNewswire.
  3. ^ Karsan N, Goadsby PJ (September 2022). "New Oral Drugs for Migraine". CNS Drugs. 36 (9): 933–949. doi:10.1007/s40263-022-00948-8. PMC 9477894. PMID 36031682.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.